Viral Genetics subsidiary VG Energy has received independent confirmation from BioProcess Algae which imply the use of VG's proprietary technology in large-scale commercial production of biofuels, high-value oils used in cosmetics, food and nutraceuticals.

The study, part of the two step viability study, verified an increase in yields of algae oils following treatment with VG’s metabolic disruption technology additives.

Viral Genetics CEO Haig Keledjian said the results will aid in completing the next phase of this particular study.

BioProcess Algae initially performed a feasibility assessment study which recognized an increase in mean nile red fluorescence after 48 hours, verifying the bench-level results of VG’s lipid enhancement technology.

The study reviewed algal strains provided by VG and additional strains from BioProcess Algae.

The company plans to undertake a dosage response study (DRS) followed by testing at industrial-scale studies.

The DRS, expected to be complete completed within a month, will test optimal dosage for the highest lipid outcome in the plant strains selected.